Multiple Sclerosis (MS) Drug Market

RECENT NEWS
newratings.com  Jul 17  Comment 
WASHINGTON (dpa-AFX) - Alkermes plc (ALKS) Thursday said it has begun its phase 1 clinical trial of ALKS 8700, an investigational monomethyl fumarate molecule, for the treatment of multiple sclerosis. The double -blind study will evaluate the...
Benzinga  Jul 9  Comment 
Biogen Idec (NASDAQ: BIIB) moved up a bit after a Deutsche Bank analyst on Wednesday talked up prospects for one of its multiple sclerosis drug candidate. If the drug gets marketing approval "the stock could move up by $30 to $100 in a single...
MedPage Today  Jul 8  Comment 
(MedPage Today) -- Patients with intracerebral hemorrhage showed improved outcomes when given fingolimod (Gilenya), the oral multiple sclerosis drug, compared with standard care alone in a small trial, researchers said.
FiercePharma  Jun 26  Comment 
Biogen's multiple sclerosis drug Tecfidera has racked up $1.38 billion in sales since its launch last April, and now the company can claim another feather in the drug's cap: It has the best safety profile of any of its peers. That's the...
NPR  Jun 23  Comment 
Jason DaSilva was diagnosed with multiple sclerosis at age 25. He has applied his skills as a documentary filmmaker to show what it's like to quickly lose the ability to walk.
newratings.com  Jun 17  Comment 
BERLIN (dpa-AFX) - German drug maker Merck KGaA (MKGAY.PK) announced Tuesday that it has reached a mutual agreement with Ono Pharmaceutical Co., Ltd. (OPHLF.PK) Osaka, Japan, to terminate the license agreement on ceralifimod (ONO-4641) because it...
FierceBiotech  Jun 16  Comment 
Biogen Idec and AbbVie announced Monday morning that their once-monthly multiple sclerosis drug daclizumab has cleared key hurdles in a Phase III study, setting the stage for a marketing pitch to regulatory authorities.
SeekingAlpha  Jun 12  Comment 
By Jason Napodano: We recently took a detailed look at BrainStorm Cell Therapeutics, Inc. (OTCQB:BCLI). BrainStorm is a biotechnology company developing adult stem cell therapies for a range of neurodegenerative diseases, including Amyotrophic...
SeekingAlpha  Jun 11  Comment 
By Stephen Simpson, CFA: Receptos (RCPT) has given its shareholders a pretty wild ride, even for an early-stage biotech. Up around 125% from when I wrote on it as a Top Idea and 39% from my Christmas Eve update, the intervening time has seen the...
FierceBiotech  Jun 10  Comment 
Last year Receptos pulled off one of the most successful biotech IPOs in a red-hot market for new offerings, largely on the promise of a midstage study underway for its oral multiple sclerosis drug. And this morning investors spurred a 35% spike...




 
TOP CONTRIBUTORS

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki